Seeking Harmonization in Nanomedicines Regulatory Framework - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Seeking Harmonization in Nanomedicines Regulatory Framework
Nanomedicines have been authorized by European licensing agencies for more than 30 years but are still posing regulatory difficulties.


Pharmaceutical Technology
Volume 37, Issue 8, pp. 28-30


Sean Milmo
Planned launches of generic versions of first-generation nanomedicines and the emergence of a second generation of more-complex nanotechnologies in healthcare are now becoming a big challenge for licensing agencies. Unsurprisingly, the pharmaceutical industry has its doubts about the exact regulatory requirements for approval of innovative nanosubstances in medicinal products. The uncertainties are not only confined to Europe but also other developed regions such as North America, mainly due to the gaps in knowledge about the safety of nanomedicines derived from recent advances in nanotechnologies.

"The industry wants greater clarity among regulators, more uniform standards, and more harmonization," Beat Loeffler, chief executive of the European Foundation for Clinical Nanomedicine (CLINAM), Basel, Switzerland, told Pharmaceutical Technology. "There is a feeling that the regulators do not know what they want." An annual international conference on clinical nanomedicines, organized jointly at Basel in June 2013 by CLINAM and the European Technology Platform on Nanomedicine (ETPN), called for greater consistency among regulators in dealing with new nanopharmaceutical products.

Safety requirements
In Europe, the safety rules on nanosubstances in medicinal products can be particularly perplexing because in many cases, the nanotechnologies are applied to drug-delivery systems, carriers, and imaging agents. As a result, the products have been categorized as combination products or medical devices rather than medicines. In the European Union (EU), this categorization has given much more scope for the regulatory authorities of the 28 EU member states to approve nanomedicines rather than the European Medicines Agency (EMA), whose main responsibility is the approval of pharmaceuticals.

Some national governments have been taking their own regulatory initiatives on the management of nanosubstances in medicines and other products because of the reluctance of the European Commission (EC) to tighten up EU rules in the area. Last year, after a regulatory review on controls of nanomaterials, the EC decided to leave EU legislation on nanotechnology unchanged. Instead, the EC stated that the safety of nanomaterials should be assessed on a case-by-case basis on the grounds that they are similar to normal substances in that some may be toxic and some may not.

In an earlier recommendation, made in October 2011, the EC provided leeway for national governments to apply their own controls on nanomaterials by recommending a broad definition of "nanomaterial." A material was defined as "nano" when it contained 50% or more particles in the size range of 1–100 nm. The EC also acknowledged that because of "special circumstances" in the pharmaceutical sector, the recommendation of an upper limit of 100 nm should "not prejudice the use of the term nano when defining certain pharmaceuticals and medical devices."

France has been among the most ambitious EU member states in introducing a new nanotechnology legislation, which came into effect in May this year, but which has, so far, not raised any significant opposition among French pharmaceutical companies. Its main requirement is that manufacturers, importers, and distributors of engineered nanosubstances make annual declarations to the French government of the amounts they are placing on the national market with details of their uses.

"This legislation is not a hurdle and the provision for annual declaration encourages transparency, which is a desirable objective," explains Laurent Levy, chief executive of Nanobiotix, Paris, a nanomedicine company and a member of the biotechnology committee of the French Pharmaceutical Companies Association. The increase in new nanomaterial legislation at the national level in Europe is, however, causing some nanomedicine companies to see regulation as being an obstacle to innovation.

"Small and medium enterprises (SMEs), in particular, are regarding regulation in nanotechnology as a barrier," Levy, who is also vice-chairman of the ETPN, an EU-funded research organization, said in an interview with Pharmaceutical Technology. "But once they start interacting with the regulatory authorities about their new products, they become much less concerned because they are in a dialogue with the authorities during the development of their nanoproducts, and therefore, will know what is expected of them."

Nanobiotix has been keeping in close contact with the French National Agency for the Safety of Medicines and Healthcare Products (ANMS) in the development of a nanoparticle-enhanced radiotherapy technology. In June 2013, ANMS authorized the company to start a clinical trial of the technology for the treatment of head and neck cancer.

The Nanobiotix technology, however, is an example of disparities outside Europe in the international classification of nanomedicines. In Europe, it has been categorized as a medical device, while in the US, FDA considers it to be a drug. As a result, Nanobiotix reckons its first products will reach the market more quickly in Europe than in the US because European national authorities responsible for licensing medical devices require fewer clinical trials than with pharmaceuticals.

"There may be a bit of a difference in the time to market between Europe and the US, but in the end, you have to meet the same regulatory requirements of demonstrating an acceptable benefit-to-risk ratio," explained Levy.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here